ThomasNet News Logo
Sign Up | Log In | ThomasNet Home | Promote Your Business

OncoMed Pharmaceuticals CEO testifies on behalf of BIO.

Print | 
Email |  Comment   Share  
December 19, 2013 - House Committee on Oversight & Government Reform, Subcommittee on Energy Policy, Health Care & Entitlements held a hearing entitled, "FDA Check-Up: Drug Development and Manufacturing Challenges." Paul Hastings, Chairman and CEO of OncoMed Pharmaceuticals and Chairman of BIO’s Emerging Companies Section Governing Board, presented testimony emphasizing the positive indicators that demonstrate the biopharma industry is rebounding, but significant financial and regulatory challenges remain.

OncoMed Pharmaceuticals CEO Testifies on Behalf of BIO at Congressional Hearing on FDA Drug Development and Manufacturing Challenges


Biotechnology Industry Organization
1201 Maryland Ave., SW, Ste. 900
Washington, DC, 20024
USA



Press release date: December 12, 2013

WASHINGTON--Today, the House Committee on Oversight & Government Reform, Subcommittee on Energy Policy, Health Care & Entitlements held a hearing entitled, “FDA Check-Up: Drug Development and Manufacturing Challenges.” Paul Hastings, Chairman and Chief Executive Officer of California-based OncoMed Pharmaceuticals and Chairman of BIO’s Emerging Companies Section Governing Board, presented testimony at the hearing emphasizing the positive indicators that demonstrate the biopharma industry is rebounding, but significant financial and regulatory challenges remain.

“FDA Check-Up: Drug Development and Manufacturing Challenges.”

Hastings highlighted the need to advance the regulatory environment so that it fosters biopharma innovation. Among his recommendations, Hastings emphasized the need to eliminate the sequestration of industry user fees and expedite drug development for serious and life-threatening diseases by expanding the existing Accelerated Approval pathway and by facilitating the new Breakthrough Therapy Designation process. Furthermore, Hastings asserted that encouraging scientific dialogue and interactive FDA-sponsor communication and incorporating patient perspectives in balancing benefits and risks are critically important to the drug development and review process.

Excerpts from the testimony are below, and can be attributed directly to Paul Hastings:

“Key provisions of PDUFA V and FDASIA, if implemented successfully, could significantly improve the efficiency and effectiveness of clinical development of innovative drugs by increasing scientific dialogue and enabling the utilization of modern tools and approaches to drug development.

“In addition to the primary mission of developing and providing new medicines and improving the lives of patients, the biopharma industry is and will be an important sector in a 21st century innovation driven U.S. economy.

“This year we have seen positive signs that the biotechnology industry is recovering from the economic crisis of 2007 and 2008, but the financial and regulatory environment continues to pose significant challenges to innovative drug and biologic developers.

“Our industry faces intense competition from other countries, as well as increasing R&D costs, regulatory challenges, and a contracted funding environment. It is vital that policies protect the intellectual property of these companies as any weakening of those protections will have deleterious impact on the ability to attract the necessary and long-term investment required to research, develop and ultimately make new medicines available to the public.

“I have over 27 years of experience in the biopharmaceutical industry. At OncoMed, we are at the cutting edge of oncology research. The biopharma industry is working on treatments and therapies that have the potential to deliver new solutions to our most pressing health care needs and is a key element of an innovation-driven economy.

“By harnessing the power of molecular biology and genomics, we have come a long way in turning incurable diseases to treatable diseases, increasing the ability of patients to be independent, and improving the quality of lives for many patients suffering from chronic and life-threatening diseases. Improving the quality of life, decreasing hospitalizations and allowing patients to live longer, more independent lives is not only a public health goal – it is a national imperative.”

The full written testimony can be accessed here, and a guest blog post by Paul Hastings can be found here. For more information on the latest advancements and policies impacting the biotech industry, please visit www.bio.org.

About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter.” Subscribe to the BIO Newsletter.

Upcoming BIO Events

BIO CEO & Investor Conference
February 10–11, 2014
New York, NY

BIO Asia International Conference
April 8-9, 2014
Tokyo, Japan

World Congress on Industrial Biotechnology
May 12-15, 2014
Philadelphia, PA

BIO International Convention
June 23-26, 2014
San Diego, CA

Livestock Biotech Summit
September 16-18, 2014
Sioux Falls, SD

Contacts
Biotechnology Industry Organization (BIO)
Tracy Cooley, APR, 202-312-9274
Web: www.bio.org
Blog: www.biotech-now.org
Twitter: @IAmBiotech
Print | 
Email |  Comment   Share  
Contacts: View detailed contact information.


 

Post a comment about this story

Name:
E-mail:
(your e-mail address will not be posted)
Comment title:
Comment:
To submit comment, enter the security code shown below and press 'Post Comment'.
 



 See related product stories
More .....
 Visit Green and Clean Blog
  Latest from the Green and Clean Blog
 See more product news in:
Services
Green & Clean
| Featured Manufacturing Jobs
 Other News from this company:
Synthetic Biology Breaks New Ground on Renewable Chemicals
Partnering Opens for 2014 BIO International Convention with Record Number of Meetings Expected
2014 BIO International Convention to Highlight Digital Health Through Partnership with the Wireless-Life Sciences Alliance
BIO Encourages EPA to Speed Approvals of New Biofuel Pathways
2014 BIO International Convention to Feature New Innovation Zone with NIH and NSF Small Business Innovation Research Companies
More ....
 Tools for you
Watch Company 
View Company Profile
Company web site
More news from this company
E-mail this story to a friend
Save Story
Search for suppliers of
Trade Associations


Home  |  My ThomasNet News®  |  Industry Market Trends®  |  Submit Release  |  Advertise  |  Contact News  |  About Us
Brought to you by Thomasnet.com        Browse ThomasNet Directory

Copyright © 2014 Thomas Publishing Company. All Rights Reserved.
Terms of Use - Privacy Policy



Error close

Please enter a valid email address